THE FUTURE OF HEALTH CARE IN CANADA September 19, 2000 © Merck Frosst Canada & Co., 2000
page 2 OECD Health Data FIle International Health spending ( )
page 3 “There is an urgent need to get the costs of Medicare under control” BCMA Forum on Medicare Emergent Theme Medicare (all provinces) Recession Slow economic recovery Year % GDP Canadian Institute for Health Information. Average annual rate of growth in H/C % 2.6% 5.1% CANADA
page chg. C.A.G.R. Hospital Services % Physician Services % Drugs % Other Health Spending % Other Professional % Other Institution % Capital % 1 Includes administration, public health, health research 2 Includes alternative care givers of health services CANADA Canadian Institute for Health Information.
page 5
6 Merck Frosst/NVO Health Care in Canada Survey 1999.
page 7 Merck Frosst/NVO Health Care in Canada Survey Public Perception
page 8
9 èService Integration èFinancial Incentives èHealth Information èHealth Insurance
page 10 èChange Delivery System èDisease Management èControl Health Care Use
page 11 èGP Fund Holding èPrimary Care Physicians Managing Total Care or a Group of Patients èBudget Holding
page 12 è Health Information System è Report Cards è Telemedicine/Telehealth è On-line Info è On-line Adjudication è Universal Classifications
page 13 Source: Pricewaterhouse Coopers. HealthCast % Gov ’t % Gov ’t % Gov ’t % Gov ’t US Insurance Gov ’t % spending growing Growth in Medicare Increased regulation Emerging Insurance System Resulting Trends Emerging Insurance System Resulting Trends Increased private insurance choice outside US Increased Public insurance in the US Today 10% Private Tomorrow 5-7% Growth/Year Today 10% Private Tomorrow 5-7% Growth/Year European/Canadian Insurance Private % spending growing Public dissatisfaction Increased employer- sponsored insurance
page 15 Public Bureaucrats Administrators Providers PatientsTax Payers Provincial Government Federal Government Pharmaceutical Industry
page 16 BASELINE MEASURE STANDARDIZED PRACTICES EVIDENCE Operation Results Health Costs Disease Management
page 17 è Reform è Performance è Opportunity